Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195427 · ClinicalTrials.gov registry record · NA
TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds
A NA study, sponsored by Teoxane.
- Completed
- Registry status
- NA
- Development phase
- 148
- Enrollment target
NCT02195427 is a NA study that has completed, run by Teoxane. The registered enrollment target is 148 participants.
The verdict
NCT02195427, a NA study, has completed, sponsored by Teoxane.
- COMPLETED
- Registry status
- NA
- Development phase
- 148 participants
- Enrollment target
Study Summary
The purpose of this study is 1) to compare the effectiveness and safety of TEOSYAL® RHA Global Action versus Juvéderm® Ultra XC, and 2) to compare the effectiveness and safety of TEOSYAL® RHA Deep Lines versus Juvéderm® Ultra XC, in the treatment of moderate to severe nasolabial folds.
Interventions
- DEVICE TEOSYAL® RHA Global Action
- DEVICE TEOSYAL® RHA Deep Lines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02195427
The ClinicalTrials.gov registry entry for NCT02195427 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teoxane, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TEOSYAL® RHA Global Action is the first listed.
NCT02195427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02195427 about?
NCT02195427 is a clinical study titled "TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds". The purpose of this study is 1) to compare the effectiveness and safety of TEOSYAL® RHA Global Action versus Juvéderm® Ultra XC, and 2) to compare the effectiveness and safety of TEOSYAL® RHA Deep Lines versus Juvéderm® Ultra XC, in the treatment of moderate to severe nasolabial folds.
What is the current status of trial NCT02195427?
This trial is currently completed. It is a NA study. The enrollment target is 148 participants. The study started on 2014-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02195427?
The interventions under investigation include: TEOSYAL® RHA Global Action (DEVICE), TEOSYAL® RHA Deep Lines (DEVICE).
Who is sponsoring clinical trial NCT02195427?
This trial is sponsored by Teoxane, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.